A systematic review and meta-analysis of cardiovascular outcome studies, which assessed how SGLT2 inhibitors affected the incidence of major cardiovascular events (MACEs) in T2D patients categorized by age, found that age has no effect on the effectiveness profile of SGLT2 inhibitors versus placebo, with a hazard ratio (HR) of 0.83 (95% confidence interval [CI], 0.71–0.96) for those ≥65 years [31]. Here, SLC5A2 is linked to type 2 diabetes mellitus.